EPS: As of FY2025 Q1, the actual value is USD -0.42.

Segment Revenue

• General and Administrative Expenses: $3,120,060 for the three months ended March 31, 2025, compared to $1,385,981 for the same period in 2024, representing an increase of $1,734,079.
• Research and Development Expenses: $2,006,214 for the three months ended March 31, 2025, compared to $321,377 for the same period in 2024, representing an increase of $1,684,837.

Operational Metrics

• Net Loss: $5,102,408 for the three months ended March 31, 2025, compared to $1,707,358 for the same period in 2024.
• Loss from Operations: $5,126,274 for the three months ended March 31, 2025, compared to $1,707,358 for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: $3,940,994 for the three months ended March 31, 2025, compared to $1,176,933 for the same period in 2024.
• Net Cash Provided by Financing Activities: $3,759,101 for the three months ended March 31, 2025, compared to $0 for the same period in 2024.

Unique Metrics

• Accumulated Deficit: $34,006,311 as of March 31, 2025.

Future Outlook and Strategy

• Core Business Focus: The company expects to continue incurring significant operating losses and may never become profitable. It plans to finance operations through equity sales and non-dilutive funding sources.
• Non-Core Business: The company has entered into a Standby Equity Purchase Agreement with Yorkville, allowing it to sell up to $15,000,000 of common shares over 36 months.